Sanofi Loses Bid To Stay Launch Of Generic Eloxatin Law360, New York (July 06, 2009) -- A judge has denied Sanofi-Aventis US LLC's request to stay the launch of generic versions of its popular colon cancer drug Eloxatin pending appeal of a finding of noninfringement in Sanofi's suit against Sandoz Inc., Teva Pharmaceutical Industries Ltd. and others.
Judge Joel Pisano of the U.S. District Court for the District of New Jersey on Wednesday ruled that granting Sanofi's request would be “unwarranted.”...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.